U.S., Feb. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07426380) titled 'A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function.' on Feb. 17.
Brief Summary: The purpose of the study is to assess the amount of Eloralintide (LY3841136) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to healthy participants. The study drug will be administered subcutaneously (SC) (under the skin).
For each participant, the study will last about 14 weeks, excluding screening.
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition:
Kidney Disease
Renal...